Background Despite the increasing knowledge of the etiology of neuropathic pain, this type
of chronic pain is resistant to available analgesics in approximately 50% of patients and …

Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating, and dose-
limiting side effect of many chemotherapy regimens yet has limited treatments due to …

Opioid analgesics represent a critical treatment for chronic pain in the analgesic ladder of
the World Health Organization. However, their use can result in a number of unwanted side …

Birth is a critical period for the developing brain, a time when surging hormone levels help
prepare the fetal brain for the tremendous physiological changes it must accomplish upon …

Abstract CB2 cannabinoid receptors (CB2) are a promising therapeutic target that lacks
unwanted side effects of CB1 activation. However, the cell types expressing CB2 that …

Chemotherapy‐induced neuropathy (CIN) is a common complication of cancer treatment.
Although CIN is treated with antidepressants that act at serotonin (5‐HT) reuptake, the …

Chemotherapy-induced peripheral neuropathy (CIPN) is the most common off-target
adverse effects caused by various chemotherapeutic agents, such as cisplatin, oxaliplatin …

Paclitaxel (PTX) is one of the most commonly used chemotherapeutic agents for various
cancer diseases. Despite its advantages, PTX also causes behavioral deficits related to …

Background Paclitaxel is a taxane-based chemotherapeutic agent used as a treatment in
breast cancer. There is no effective prevention or treatment strategy for the most common …

Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side-effect
of all major chemotherapeutic agents. Here, we explored efficacy of voluntary exercise as a …